greeksoup/ stock research
Stock research / United States / Funds / Propel Bio Management, LLC

Propel Bio Management, LLC

CIK 1969764 · latest 13F filed 13 August 2026 · Read the filing on EDGAR

Propel Bio Management, LLC reported 29 US-listed holdings worth $191.1 million in its 13F for the quarter ended 30 June 2026, filed 13 August 2026. Its largest: Plains GP Hldgs L P (16.2%), Achieve Life Sciences Inc. (13.8%) and Corcept Therapeutics Inc. (6.2%). Against the quarter before, it opened 4 positions, added to 11, trimmed 10 and sold out of 13.

Reported holdings$191.1M+20.4% on Q1 2026
Positions29-9 on Q1 2026
The largest ten68.1%of its reported holdings
Latest 13FQ2 2026filed 13 August 2026
Where the money is
OpenedAdded toHeldTrimmed
PAGP16.2%ACHV13.8%CORT6.2%PHAT6.0%DCTH5.7%MIST5.2%CMPS4.2%KYTX4.1%ARTV3.5%ABEO3.2%AQST3.1%PALI2.8%IMUX2.6%IVA2.5%15 more20.7%

The 14 largest of its 29 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $172.4 million in 21 positions$172MQ3 24Q4 2024: $100.7 million in 21 positions$101MQ4 24Q1 2025: $86.1 million in 18 positions$86.1MQ1 25Q2 2025: $82.4 million in 16 positions$82.4MQ2 25Q3 2025: $99.9 million in 16 positions$99.9MQ3 25Q4 2025: $117.1 million in 20 positions$117MQ4 25Q1 2026: $158.7 million in 38 positions$159MQ1 26Q2 2026: $191.1 million in 29 positions$191MQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What its reported holdings returned

Held through each quarter, the holdings it reported returned -23.6% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.

Its reported holdingsThe S&P 500
5075100125Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Its holdings -23.6%S&P 500 +30.2%

Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.

What it did on the quarter

Opened 4Added 11Held 4Trimmed 10Sold out 13
Opened: 4Added: 11Held: 4Trimmed: 10Sold out: 13

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 4

  1. Immunic Inc. IMUX$5.0 million
  2. Scynexis Inc. SCYX$2.2 million
  3. Silence Therapeutics PLC SLN$2.1 million
  4. Sagimet Biosciences Inc. SGMT$973,037

Added to 11

  1. Artiva Biotherapeutics Inc. ARTV+550,067 shares · +376%
  2. Milestone Pharmaceuticals Inc. (mist) MIST+3.3 million shares · +80%
  3. Palisade Bio Inc. PALI+1.5 million shares · +132%
  4. Aquestive Therapeutics Inc. AQST+731,409 shares · +103%
  5. Phathom Pharmaceuticals Inc. PHAT+209,086 shares · +25%
  6. Kyverna Therapeutics Inc. KYTX+238,777 shares · +37%
  7. Inventiva SA IVA+556,534 shares · +77%
  8. Achieve Life Sciences Inc. ACHV+247,593 shares · +7%

and 3 more in the table below

Trimmed 10

  1. Compass Pathways PLC CMPS-168,963 shares · -23%
  2. Abeona Therapeutics Inc. ABEO-346,829 shares · -26%
  3. 4D Molecular Therapeutics in FDMT-127,766 shares · -34%
  4. Delcath Sys Inc. DCTH-108,238 shares · -11%
  5. Celldex Therapeutics Inc. CLDX-27,669 shares · -21%
  6. Corcept Therapeutics Inc. CORT-11,329 shares · -8%
  7. Zevra Therapeutics Inc. ZVRA-28,874 shares · -10%
  8. Eyepoint Pharmaceuticals Inc. EYPT-24,080 shares · -11%

and 2 more in the table below

Sold out of 13

  1. Vor Biopharma Inc. VOR$5.6 million last quarter
  2. Viridian Therapeutics Inc. VRDN$4.1 million last quarter
  3. Oculis Holding AG OCS$3.3 million last quarter
  4. Trevi Therapeutics Inc. TRVI$2.6 million last quarter
  5. Immunic Inc. IMUX$2.6 million last quarter
  6. Coherus Biosciences Inc. CHRS$2.4 million last quarter
  7. Kalaris Therapeutics Inc KLRS$1.7 million last quarter
  8. Uniqure NV QURE$1.7 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Plains GP Hldgs L P PAGP1.3M$30.9 million16.16%no change
Achieve Life Sciences Inc. ACHV4.0M$26.3 million13.79%+247.6K
Corcept Therapeutics Inc. CORT136.5K$11.9 million6.21%-11.3K
Phathom Pharmaceuticals Inc. PHAT1.1M$11.4 million5.96%+209.1K
Delcath Sys Inc. DCTH871.5K$11.0 million5.74%-108.2K
Milestone Pharmaceuticals Inc. (mist) MIST7.4M$10.0 million5.21%+3.3M
Compass Pathways PLC CMPS573.1K$8.1 million4.24%-169.0K
Kyverna Therapeutics Inc. KYTX883.2K$7.9 million4.12%+238.8K
Artiva Biotherapeutics Inc. ARTV696.4K$6.8 million3.54%+550.1K
Abeona Therapeutics Inc. ABEO983.1K$6.1 million3.18%-346.8K
Aquestive Therapeutics Inc. AQST1.4M$6.0 million3.14%+731.4K
Palisade Bio Inc. PALI2.6M$5.4 million2.82%+1.5M
Immunic Inc. IMUX325.0K$5.0 million2.61%new
Inventiva SA IVA1.3M$4.8 million2.53%+556.5K
Sab Biotherapeutics Inc. SABS1.1M$4.2 million2.20%+63.8K
Orchestra Biomed Holdings in OBIO896.7K$3.9 million2.02%no change
Celldex Therapeutics Inc. CLDX103.7K$3.9 million2.02%-27.7K
Zevra Therapeutics Inc. ZVRA253.5K$3.6 million1.90%-28.9K
Ocular Therapeutix Inc. OCUL358.0K$3.5 million1.84%-24.4K
4D Molecular Therapeutics in FDMT252.7K$3.4 million1.76%-127.8K
Ovid Therapeutics Inc. OVID1.1M$3.0 million1.57%+194.1K
Eyepoint Pharmaceuticals Inc. EYPT191.7K$2.7 million1.43%-24.1K
Upstream Bio Inc. UPB350.4K$2.4 million1.27%+8.6K
Scynexis Inc. SCYX543.5K$2.2 million1.16%new
Silence Therapeutics PLC SLN191.7K$2.1 million1.10%new
Athira Pharma Inc. LONA149.3K$1.4 million0.72%no change
Maze Therapeatics MAZE43.8K$1.3 million0.68%no change
Corvus Pharmaceuticals Inc. CRVS70.4K$1.1 million0.55%-15.4K
Sagimet Biosciences Inc. SGMT125.9K$973,0370.51%new
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 13 it sold out of are in the box above.